Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT07508254
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Sponsor
- Punjab Institute of Cardology
- Registry
-
NCT07508254
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Pakistan
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07508254. Randomized; no masking; primary purpose treatment. Start 2026-05-01 (anticipated); primary completion 2026-10-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
- Acronym
- TLD-ACS
- Condition
- Acute Coronary Syndromes (ACS)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Atorvastatin 40 Mg Oral Tablet
- Intervention (Drug)
- Ezetimibe 10 mg
- Intervention (Drug)
- Bempedoic Acid 180 MG Oral Tablet
- Lead sponsor
- Punjab Institute of Cardology
Record details
- Record id
cardio:ct-nct07508254- Content hash
bf4f954a3b12a59635d406231dbfd00ff6a0fe36fda4f980a33218781c422036